1. Home
  2. Live Updates
  3. Myovant sciences forward looking statement

Myovant Sciences Forward Looking Statement News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Myovant sciences forward looking statement. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Myovant Sciences Forward Looking Statement Today - Breaking & Trending Today

Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in ...


Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in .
Myovant Sciences, Inc.December 28, 2020 GMT
Myovant and Pfizer to jointly develop and commercialize ORGOVYX™
 (relugolix) and relugolix combination tablet and share profits and expenses in the U.S. and Canada
Myovant to receive an upfront payment of $650 million in addition to potential regulatory and sales milestones for a total payment of up to $4.2 billion
Myovant to host conference call and webcast today at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time
BASEL, Switzerland and NEW YORK, Dec. 28, 2020 (GLOBE NEWSWIRE) Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced a collaboration to develop and commercialize relugolix – a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist – in oncology and women’s healt ....

United States , Albert Liao , Andy Schmeltz , Nick Lagunowich , Bryan Crowe , Steve Danehy , Lynn Seely , Chuck Triano , Myovant Sciences , Drug Administration , Myovant Sciences Conference Call , Exchange Commission , Myovant Sciences Contacts , Pfizer Inc , Myovant Sciences Forward Looking Statement , Myovant Sciences Inc , Sumitomo Dainippon Pharma Co Ltd , Sumitovant Biopharma Ltd , Chief Executive Officer , Global President , Pfizer Internal , New Drug Application , Investor Relations , Sumitovant Biopharma , Breakthroughs That Change Patient Lives , Pfizer News ,

Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women's Health


Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women s Health
[December 28, 2020]
Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women s Health
Myovant and Pfizer to jointly develop and commercialize ORGOVYX™
 (relugolix) and relugolix combination tablet and share profits and expenses in the U.S. and Canada
Myovant to receive an upfront payment of $650 million in addition to potential regulatory and sales milestones for a total payment of up to $4.2 billion
Myovant to host conference call and webcast today at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time
BASEL, Switzerland and NEW YORK, Dec. 28, 2020 (GLOBE NEWSWIRE) Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced a collaboration to develop and commercialize relugolix – a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist ....

United States , Albert Liao , Andy Schmeltz , Nick Lagunowich , Bryan Crowe , Steve Danehy , Lynn Seely , Chuck Triano , Myovant Sciences , Women Health , Drug Administration , Myovant Sciences Conference Call , Exchange Commission , Myovant Sciences Contacts , Pfizer Inc , Myovant Sciences Forward Looking Statement , Myovant Sciences Inc , Sumitomo Dainippon Pharma Co Ltd , Sumitovant Biopharma Ltd , Pfizer Announce Collaboration , Commercialize Relugolix , Chief Executive Officer , Global President , Pfizer Internal , New Drug Application , Investor Relations ,